| Exclusion Criteria: | 1) History of prior or concurrent central nervous system (CNS) metastases.
2) History of other primary cancer, unless: a) Curatively resected non-melanomatous skin cancer; b) Curatively treated cervical carcinoma in situ; c) Other primary solid tumor treated with curative intent and no known active disease present for >/= 5 years before enrollment.
3) Prior treatment with anti-EGFr inhibitors (eg, panitumumab, cetuximab, erlotinib, gefitinib), unless treatment was received in the adjuvant setting >/= 6 months before enrollment.
4) Prior treatment with c-Met, IGF-IR, or IGF-IIR inhibitors.
5) Prior treatment with either AMG 102 or AMG 479.
6) Use of experimental or approved systemic chemotherapy or radiotherapy </= 21 days before enrollment.
7) Use of experimental or approved targeted therapies </= 30 days before enrollment.
8) Known allergy or hypersensitivity to any component of panitumumab, AMG 102, or AMG 479.
9) History of interstitial lung disease (eg, pneumonitis, pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computerized tomography (CT) scan.
10) Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) </= 1 year before enrollment.
11) Active inflammatory bowel disease or other active bowel disease causing chronic diarrhea (defined as =/> grade 2 per CTCAE version 3.0).
12) Known positive test(s) for human immunodeficiency virus (HIV) infection, hepatitis C virus, acute or chronic active hepatitis B infection.
13) Any co-morbid disease or condition that could increase the risk of toxicity (eg, significant ascites, significant pleural effusion).
14) Serious or non-healing wound </= 35 days before enrollment.
15) Any uncontrolled concurrent illness (eg, infection, bleeding diathesis) or history of any medical condition that may interfere with the interpretation of the study results.
16) Major surgical procedure </= 35 days before enrollment or minor surgical procedure </= 14 days before enrollment. Subjects must have recovered from surgery related toxicities. Central venous catheter placement, fine needle aspiration, thoracentesis, or paracentesis is not considered a major or minor surgical procedure.
17) Other investigational procedures or drugs (ie, participation in another clinical study) are excluded </= 30 days.
18) Subject of child-bearing potential is evidently pregnant (eg, positive HCG test) or is breast feeding.
19) Man or woman of childbearing potential who is not willing to use adequate contraceptive precautions during treatment and for 6 months after the last dose of the last investigational product (men and women). Adequate contraceptive precautions includes double barrier contraceptive methods (eg, diaphragm and condom) or abstinence.
20) Previously enrolled into this study.
21) Subject unwilling or unable to comply with study requirements.
22) Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures. |